Belite Bio, Inc. is a clinical-stage biopharmaceutical company that researches and develops treatments for untreatable eye diseases involving retinal degeneration, as well as metabolic diseases. The company's primary focus is on its lead candidate, tinlarebant (LBS-008), an oral, once-daily retinol binding protein 4 (RBP4) antagonist currently in Phase 3 clinical trials for Stargardt disease type 1 (STGD1) and geographic atrophy (GA). By reducing the delivery of vitamin A to the eye, the therapy aims to prevent the accumulation of toxic byproducts that cause vision loss. Additionally, Belite Bio is developing LBS-009, a preclinical-stage anti-RBP4 oral therapy targeting liver and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes, and gout. Incorporated in the Cayman Islands and headquartered in San Diego, California, the company operates as a subsidiary of Lin Bioscience International Ltd.
